Repligen

RGENNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$10.764 B

$168.39 -5.50%

Close of 6 Nov 2026

As of 6 Nov 2026, Repligen (RGEN) has a market capitalization of $10.8B. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

—

Not reported

Earnings

$48.9M

#1568 by earnings

Shares outstanding

63,923,738

Latest filing cover page

P/E ratio

220.2

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →

#11Bio-TechneTECH$11.4B
#12Kymera TherapeuticsKYMR$10.8B
#13RepligenRGEN$10.8B
#14QiagenQGEN$10.5B
#15VaxcytePCVX$9.84B

What if Repligen were worth as much as…

Open the what-if tool →

Gold $28.2T

$441,727.51

Per share 2,623× higher

Bitcoin $1.53T

$23,901.11

Per share 142× higher

Apple $5.02T

$78,465.10

Per share 466× higher

Or at a round number

$20.0B $50.0B $100.0B $200.0B

Where these numbers come from

Share counts and financials for Repligen are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.